Skip to main content

Table 8 Variables associated with benzodiazepine use during the most recent treatment period for anxiety disordersb, c

From: Treatment adequacy of anxiety disorders among young adults in Finland

  Benzodiazepine prescribed
Variable Category OR 95 % CI
Gender Male (ref.) 1.00 -
  Female 0.66 0.16–2.63
Basic education Less than high school (ref.) 1.00 -
High school 1.46 0.37–5.81
Married or No (ref.) 1.00 -
cohabiting Yes 0.94 0.29–3.08
Comorbid No (ref.) 1.00 -
mood disorder Yes 0.66 0.20–2.21
Comorbid substance No (ref.) 1.00 -
use disorder Yes 2.30 0.57–9.26
Comorbid No (ref.) 1.00 -
personality disorder Yes *4.77 1.11–20.59
Comorbid No (ref.) 1.00 -
other disordera Yes 1.72 0.39–7.47
More than 1 anxiety No (ref.) 1.00 -
disorder Yes 0.45 0.08–2.65
  1. OR Adjusted odds ratio; 95 % CI 95 % confidence interval
  2. *p < 0.05; **p < 0.01; ***p < 0.001. These p-values indicate a significance of the difference of the odds ratios between categories tested by χ2-test. Significant differences (p < 0.05) in boldface
  3. aPsychotic, eating, sleeping, adjustment or impulse control disorder lifetime
  4. bParticipants with a single specific phobia were excluded
  5. cAll the variables were entered simultaneously into a logistic regression model, adjusting for the other factors shown in the table